

**American College of Radiology  
ACR Appropriateness Criteria®**

**Clinical Condition:** Solitary Pulmonary Nodule

**Variant 1:** Nodule  $\geq 1$  cm, low clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
CT chest without contrast	8	To detect occult calcifications, fat, bronchus sign, etc.	☼ ☼ ☼
FDG-PET whole body	8	If nodule is indeterminate on HRCT.	☼ ☼ ☼ ☼
Transthoracic needle biopsy	8	If nodule shows contrast enhancement or PET scan is positive.	NS
CT chest with contrast	6	Probably not indicated if PET performed.	☼ ☼ ☼
Watchful waiting with CT follow-up	4		NS
MRI chest with or without contrast	2		O
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>

**Variant 2:** Nodule  $\geq 1$  cm, moderate to high clinical suspicion for cancer.

Radiologic Procedure	Rating	Comments	<a href="#">RRL*</a>
CT chest without contrast	8	To detect occult calcifications, fat, bronchus sign, etc.	☼ ☼ ☼
FDG-PET whole body	8	If nodule is indeterminate on HRCT.	☼ ☼ ☼ ☼
Transthoracic needle biopsy	8	If nodule shows contrast enhancement or PET scan is positive.	NS
CT chest with contrast	6	Probably not indicated if PET performed.	☼ ☼ ☼
Watchful waiting with CT follow-up	2		NS
MRI chest with or without contrast	2		O
<b><u>Rating Scale:</u> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate</b>			<b>*Relative Radiation Level</b>

**Clinical Condition:****Solitary Pulmonary Nodule****Variant 3:****Nodule  $\leq$ 1 cm, low clinical suspicion for cancer.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><u>RRL*</u></b>
Watchful waiting with CT follow-up	8		NS
CT chest without contrast	7		☼ ☼ ☼
CT chest with contrast	3		☼ ☼ ☼
FDG-PET whole body	3		☼ ☼ ☼ ☼
Transthoracic needle biopsy	2		NS
MRI chest with or without contrast	1		O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

**Variant 4:****Nodule  $\leq$ 1 cm, moderate to high clinical suspicion for cancer.**

<b>Radiologic Procedure</b>	<b>Rating</b>	<b>Comments</b>	<b><u>RRL*</u></b>
CT chest without contrast	8		☼ ☼ ☼
Transthoracic needle biopsy	6		NS
Watchful waiting with CT follow-up	5		NS
CT chest with contrast	4		☼ ☼ ☼
FDG-PET whole body	2		☼ ☼ ☼ ☼
MRI chest with or without contrast	1		O
<b>Rating Scale:</b> 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate			<b>*Relative Radiation Level</b>

## SOLITARY PULMONARY NODULE

Expert Panel on Thoracic Imaging: Arfa Khan, MD<sup>1</sup>; Tracy J. Lee, MD<sup>2</sup>; Tan-Lucien Mohammed, MD<sup>3</sup>; Poonam V. Batra MD<sup>4</sup>; Jud W. Gurney, MD<sup>5</sup>; Linda B. Haramati, MD<sup>6</sup>; Jean Jeudy, MD<sup>7</sup>; Heber MacMahon, MD<sup>8</sup>; Anna Rozenshtein, MD<sup>9</sup>; Kay H. Vydareny, MD<sup>10</sup>; Lacey Washington, MD<sup>11</sup>; Larry Kaiser, MD<sup>12</sup>; Suhail Raof, MBBS.<sup>13</sup>

### **Summary of Literature Review**

The solitary pulmonary nodule is traditionally defined as a relatively spherical opacity 3 cm or less in diameter surrounded by lung parenchyma [1]. There should be no associated abnormality, including atelectasis or hilar adenopathy. This definition is based predominantly on information obtained from the chest radiograph.

The ever-expanding role of computed tomography (CT) in medical imaging is leading to additional insights into this definition. The more generic term to describe a nodule is a focal opacity. This term encompasses those abnormalities that are solid, semisolid and nonsolid (ground-glass opacity). The incidence of solitary nodules was traditionally believed to be in the range of approximately 150,000 new cases per year in the United States [2]. However, this figure was based on chest radiographic findings and did not include all of the smaller nodules detected with CT. When these are included, the incidence dramatically increases, although precise estimates are not available. In particular, CT has placed us in the domain of finding smaller nodules. Although a precise definition of small has not been standardized, it is generally considered to be in the range of less than 1 cm. As with radiographically detected nodules, the primary concern in evaluating even these smaller nodules is the ability to exclude malignancy.

The radiologist is now in the position of being able to detect many more nodules. In addition there are many more diagnostic tests available. It should be noted that for

all of these tests, the accuracy tends to decrease with smaller nodule size. Diagnostic tests range from noninvasive decision theoretic approaches to major surgery. It is largely the role of the radiologist to help select the appropriate management strategy.

Theoretic approaches for decision-making include the use of Bayes theorem, logistic regression models, and neural network analysis [3-6]. These approaches are useful primarily in estimating the probability of malignancy for a particular nodule. Information from the radiologic appearance of the nodule such as size, shape, and edge characteristics can be combined with clinical risk information such as age and smoking history to produce an overall probability for malignancy. If this probability can be set sufficiently low, strategies that include observing nodules for interval change can be advocated. While this policy of watchful waiting has generally not been advocated, it is becoming increasingly clear that, under certain circumstances, it is appropriate [7]. Similarly, these estimates can be combined with subsequent imaging information to further define the probability of malignancy and guide additional steps in the diagnostic work-up [8].

The choice of imaging test to evaluate solitary nodules is extensive. However, only two findings are considered to be sufficient to preclude further evaluation: calcification in a benign pattern and stability in size for over two years. Both of these criteria have been known since the early 1950s [9,10]. However, only a small number of nodules meet these criteria; the majority falls in the category of indeterminate. Other radiographic features—including size, shape, edge characteristics, and density—have not yet been found to be sufficiently accurate to characterize nodules. Extensive work is now being done using advanced image processing techniques to further advance this capability. In particular, this includes the ability to utilize information that provide 3-dimensional characteristics. This field is rapidly developing and is now readily available with the newer multirow CT scanners. Volumetric analysis measures growth of nodules in short time intervals, allowing for assessment of doubling times. This is an extension of the concept of watchful waiting. Factors that affect the reproducibility of nodule volume measurement on CT include nodule size at detection and the presence of patient-induced artifacts [11]. The only current guidelines for management of small nodules in the radiological literature are those that have been developed in the context of lung cancer screening. Based on a retrospective review of 2,897 baseline screening scans, the authors determined that a noncalcified nodule measuring <5 mm should have a follow-up scan in one year [12]. The criteria have also been recently revised by the Fleischner Society [13].

Recently, computed-aided diagnosis (CAD) systems have been developed for lung nodule detection on CT. CAD has the potential to improve radiologists' diagnostic accuracy in distinguishing small benign nodules from

<sup>1</sup>Principal Author and Panel Chair, Long Island Jewish Medical Center, New Hyde Park, New York.

<sup>2</sup>Research Author, Long Island Jewish Medical Center, New Hyde Park, New York.

<sup>3</sup>Panel Vice-chair, Cleveland Clinic Foundation, Cleveland, Ohio.

<sup>4</sup>David Geffen School of Medicine, Los Angeles, California.

<sup>5</sup>University of Nebraska, Omaha, Nebraska.

<sup>6</sup>Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.

<sup>7</sup>University of Maryland Medical Center, Baltimore, Maryland.

<sup>8</sup>University of Chicago Hospital, Chicago, Illinois.

<sup>9</sup>Columbia Presbyterian Medical Center, New York, New York.

<sup>10</sup>Emory University Hospital, Atlanta, Georgia.

<sup>11</sup>Duke University Medical Center, Durham, North Carolina.

<sup>12</sup>University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, Society of Thoracic Surgeons.

<sup>13</sup>New York Methodist Hospital, Brooklyn, New York, American College of Chest Physicians.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

Reprint requests to: Department of Quality & Safety, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191-4397.

malignant ones on high-resolution CT (HRCT) [14,15]. Recent studies have also shown that CAD schemes would be useful in clinical practice by providing radiologists with computer output as a “second opinion” [16].

Contrast-enhanced CT of solitary pulmonary nodules has also been used to differentiate benign from malignant nodules. Results from a large multicenter study found that contrast-enhanced CT has a sensitivity of 98% and a specificity of 58% when using a cutoff of 15 Hounsfield units for enhancement. This led the authors to conclude that absence of enhancement is a strong predictor of benignity [17]. Recent studies have also shown that analysis of combined wash-in and washout characteristics at dynamic contrast-enhanced multidetector row CT showed 92% accuracy for distinguishing benign from malignant nodules [18]. The extent of enhancement reflects underlying nodule angiogenesis [19]. Limitations of the technique relate to its nonspecific nature for inflammatory disease and an incomplete knowledge base for small nodules. More recently, contrast-enhanced dynamic magnetic resonance imaging (MRI) of solitary pulmonary nodules has shown to be comparable to CT for differentiating between benign and malignant pulmonary nodules with a sensitivity of 96%, specificity of 88%, and accuracy of 92% [20-22].

Positron emission tomography (PET) using fluorine-18-2fluoro-2-deoxy-D-glucose (FDG) has gained a major role in the evaluation of patients with solitary pulmonary nodules. This technique relies on measuring glucose metabolism, which has been shown to be different between benign and malignant nodules. Many studies have demonstrated the accuracy of FDG-PET in evaluating solitary pulmonary nodules [23]. The sensitivity and specificity for this technique, as reported in the literature, have ranged from 83%-97% and from 69%-100%, respectively. FDG-PET has a higher specificity and only slightly reduced sensitivity when compared to nodule-enhancement CT [24]. Limitations of PET scanning include its inability to accurately characterize certain types of lesions, including bronchoalveolar carcinoma and typical carcinoid tumors. It is also limited in its ability to characterize nodules less than 1 cm in diameter and it may give false positive results in patients with active infections and inflammatory diseases.

In view of the necessity to approach near certainty with the diagnostic evaluation due to the aggressive nature of lung cancer, tests that provide pathologic material are quite useful. Currently, such diagnostic tests include transthoracic needle biopsy (TNB), bronchoscopy, video-assisted thorascopy (VATS), and thoracotomy. The relative roles of these procedures are not well defined in existing literature, perhaps because of the lack of a defined sensitivity and specificity for the semi-invasive tests. Both TNB [25-28] and bronchoscopy [29] are highly dependent on nodule size and location and on the skill of the person performing the procedure. In general, TNB has a higher sensitivity and specificity than bronchoscopy, and therefore it is usually a more

appropriate test in diagnosing solitary nodules. CT fluoroscopy-guided lung biopsy using the new automated cutting needle provides a high degree of diagnostic accuracy, allows for the specific characterization of lung nodules, and can be performed safely with a sensitivity of 95.1%, specificity of 100%, and accuracy of 96.2% [30]. The role of TNB relative to the surgical approach depends primarily on the ability to make a benign diagnosis. If its only role is to confirm malignancy, then it only adds to the cost of the overall work-up, although there can be some use in confirming malignancy before surgery, such as diagnosing small-cell carcinoma. The diagnosis of benign disease using TNB is generally divided into three broad categories: specific benign diagnosis, nonspecific benign diagnosis, and nondiagnostic biopsy.

Recent reports suggest that the number of specific benign diagnoses can be increased using core needles, although this occurs at the cost of increasing complication rates. In general, for benign nonspecific and nondiagnostic studies, repeat biopsy or resection is necessary [31]. Compared to thoracotomy, VATS offers the benefit of lower perioperative morbidity and decreased length of hospital stay. VATS is most successful for peripheral lesions and some central lesions in the lower lobe, and it is the surgical method of choice for diagnosis and resection of pulmonary nodules. If the nodules are too small, or located too deeply to be detected thorascopically, preoperative CT-guided placement of a pulmonary nodule-marker system like methylene blue or wires is a safe and accurate method of localizing pulmonary nodules at thorascopy [32,33].

In view of the variety of diagnostic tests available and the variable accuracy of the different diagnostic techniques, no single algorithm for work-up is generally accepted. It has been found to vary from institution to institution. This is probably appropriate given the varying prevalence of lung disease in different parts of the country, varying skill levels of operators, and varying availability of equipment.

### **Relative Radiation Level Information**

Potential adverse health effects associated with radiation exposure are an important factor to consider when selecting the appropriate imaging procedure. Because there is a wide range of radiation exposures associated with different diagnostic procedures, a relative radiation level (RRL) indication has been included for each imaging examination. The RRLs are based on effective dose, which is a radiation dose quantity that is used to estimate population total radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher risk from exposure, both because of organ sensitivity and longer life expectancy (relevant to the long latency that appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower as compared to those specified for adults (see Table below). Additional information regarding radiation dose assessment for imaging examinations can be found in the ACR Appropriateness Criteria® [Radiation Dose Assessment Introduction](#) document.

Relative Radiation Level Designations		
Relative Radiation Level*	Adult Effective Dose Estimate Range	Pediatric Effective Dose Estimate Range
O	0 mSv	0 mSv
☼	<0.1 mSv	<0.03 mSv
☼☼	0.1-1 mSv	0.03-0.3 mSv
☼☼☼	1-10 mSv	0.3-3 mSv
☼☼☼☼	10-30 mSv	3-10 mSv
☼☼☼☼☼	30-100 mSv	10-30 mSv

\*RRL assignments for some of the examinations cannot be made, because the actual patient doses in these procedures vary as a function of a number of factors (eg, region of the body exposed to ionizing radiation, the imaging guidance that is used). The RRLs for these examinations are designated as NS (not specified).

### Supporting Document(s)

- [ACR Appropriateness Criteria® Overview](#)
- [Procedure Information](#)
- Evidence table under review

### References

1. Tuddenham WJ. Glossary of terms for thoracic radiology: recommendations of the Nomenclature Committee of the Fleischner Society. *AJR* 1984; 143(3):509-517.
2. Lillington G. *Disease of the month*. Mosby-Year Book, Inc.; 1991.
3. Gurney JW. Determining the likelihood of malignancy in solitary pulmonary nodules with Bayesian analysis. Part I. Theory. *Radiology* 1993; 186(2):405-413.
4. Henschke CI, Yankelevitz DF, Mateescu I, Brettle DW, Rainey TG, Weingard FS. Neural networks for the analysis of small pulmonary nodules. *Clin Imaging* 1997; 21(6):390-399.
5. Nakamura K, Yoshida H, Engelmann R, et al. Computerized analysis of the likelihood of malignancy in solitary pulmonary nodules with use of artificial neural networks. *Radiology* 2000; 214(3):823-830.
6. Swensen SJ, Silverstein MD, Ilstrup DM, Schleck CD, Edell ES. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. *Arch Intern Med* 1997; 157(8):849-855.
7. Ko JP. Lung nodule detection and characterization with multi-slice CT. *J Thorac Imaging* 2005; 20(3):196-209.
8. Matsuki Y, Nakamura K, Watanabe H, et al. Usefulness of an artificial neural network for differentiating benign from malignant pulmonary nodules on high-resolution CT: evaluation with receiver operating characteristic analysis. *AJR* 2002; 178(3):657-663.
9. Aufses AH. Differential diagnosis between the early infiltrate or tuberculous and carcinoma of lung. *TuberculoLOGY* 1949; 210:72-78.
10. Good CA. Management of patient with solitary mass in the lung. *Chicago M Soc Bull* 1953; 55:893-896.
11. Kostis WJ, Yankelevitz DF, Reeves AP, Fluture SC, Henschke CI. Small pulmonary nodules: reproducibility of three-dimensional volumetric measurement and estimation of time to follow-up CT. *Radiology* 2004; 231(2):446-452.
12. Henschke CI, Yankelevitz DF, Naidich DP, et al. CT screening for lung cancer: suspiciousness of nodules according to size on baseline scans. *Radiology* 2004; 231(1):164-168.

13. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology* 2005; 237(2):395-400.
14. Brown MS, Goldin JG, Rogers S, et al. Computer-aided lung nodule detection in CT: results of large-scale observer test. *Acad Radiol* 2005; 12(6):681-686.
15. Li F, Aoyama M, Shiraiishi J, et al. Radiologists' performance for differentiating benign from malignant lung nodules on high-resolution CT using computer-estimated likelihood of malignancy. *AJR* 2004; 183(5):1209-1215.
16. Li Q, Li F, Suzuki K, et al. Computer-aided diagnosis in thoracic CT. *Semin Ultrasound CT MR* 2005; 26(5):357-363.
17. Swensen SJ, Viggiano RW, Midthun DE, et al. Lung nodule enhancement at CT: multicenter study. *Radiology* 2000; 214(1):73-80.
18. Jeong YJ, Lee KS, Jeong SY, et al. Solitary pulmonary nodule: characterization with combined wash-in and washout features at dynamic multi-detector row CT. *Radiology* 2005; 237(2):675-683.
19. Yi CA, Lee KS, Kim EA, et al. Solitary pulmonary nodules: dynamic enhanced multi-detector row CT study and comparison with vascular endothelial growth factor and microvessel density. *Radiology* 2004; 233(1):191-199.
20. Kim JH, Kim HJ, Lee KH, Kim KH, Lee HL. Solitary pulmonary nodules: a comparative study evaluated with contrast-enhanced dynamic MR imaging and CT. *J Comput Assist Tomogr* 2004; 28(6):766-775.
21. Schaefer JF, Vollmar J, Schick F, et al. Solitary pulmonary nodules: dynamic contrast-enhanced MR imaging--perfusion differences in malignant and benign lesions. *Radiology* 2004; 232(2):544-553.
22. Kono R, Fujimoto K, Terasaki H, et al. Dynamic MRI of solitary pulmonary nodules: comparison of enhancement patterns of malignant and benign small peripheral lung lesions. *AJR* 2007; 188(1):26-36.
23. Mavi A, Lakhani P, Zhuang H, Gupta NC, Alavi A. Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. *Radiol Clin North Am* 2005; 43(1):1-21, ix.
24. Christensen JA, Nathan MA, Mullan BP, Hartman TE, Swensen SJ, Lowe VJ. Characterization of the solitary pulmonary nodule: 18F-FDG PET versus nodule-enhancement CT. *AJR* 2006; 187(5):1361-1367.
25. Geraghty PR, Kee ST, McFarlane G, Razavi MK, Sze DY, Dake MD. CT-guided transthoracic needle aspiration biopsy of pulmonary nodules: needle size and pneumothorax rate. *Radiology* 2003; 229(2):475-481.
26. Wallace MJ, Krishnamurthy S, Broemeling LD, et al. CT-guided percutaneous fine-needle aspiration biopsy of small (< or =1-cm) pulmonary lesions. *Radiology* 2002; 225(3):823-828.
27. Westcott JL. Needle biopsy of the chest. In: Tavares J, Ferruci J, eds. *Imaging- Diagnosis- Intervention*. Philadelphia, Pa.: Lippincott; 1993:1-3.
28. Yankelevitz DF, Wisnivesky JP, Henschke CI. Comparison of biopsy techniques in assessment of solitary pulmonary nodules. *Semin Ultrasound CT MR* 2000; 21(2):139-148.
29. Baaklini WA, Reinoso MA, Gorin AB, Sharafkaneh A, Manian P. Diagnostic yield of fiberoptic bronchoscopy in evaluating solitary pulmonary nodules. *Chest* 2000; 117(4):1049-1054.
30. Yamagami T, Iida S, Kato T, et al. Usefulness of new automated cutting needle for tissue-core biopsy of lung nodules under CT fluoroscopic guidance. *Chest* 2003; 124(1):147-154.
31. Savage C, Walsler EM, Schnadig V, Woodside KJ, Ustuner E, Zwischenberger JB. Transthoracic image-guided biopsy of lung nodules: when is benign really benign? *J Vasc Interv Radiol* 2004; 15(2 Pt 1):161-164.
32. Dendo S, Kanazawa S, Ando A, et al. Preoperative localization of small pulmonary lesions with a short hook wire and suture system: experience with 168 procedures. *Radiology* 2002; 225(2):511-518.
33. Hanninen EL, Langrehr J, Raakow R, et al. Computed tomography-guided pulmonary nodule localization before thorascopic resection. *Acta Radiol* 2004; 45(3):284-288.

The ACR Committee on Appropriateness Criteria and its expert panels have developed criteria for determining appropriate imaging examinations for diagnosis and treatment of specified medical condition(s). These criteria are intended to guide radiologists, radiation oncologists and referring physicians in making decisions regarding radiologic imaging and treatment. Generally, the complexity and severity of a patient's clinical condition should dictate the selection of appropriate imaging procedures or treatments. Only those examinations generally used for evaluation of the patient's condition are ranked. Other imaging studies necessary to evaluate other co-existent diseases or other medical consequences of this condition are not considered in this document. The availability of equipment or personnel may influence the selection of appropriate imaging procedures or treatments. Imaging techniques classified as investigational by the FDA have not been considered in developing these criteria; however, study of new equipment and applications should be encouraged. The ultimate decision regarding the appropriateness of any specific radiologic examination or treatment must be made by the referring physician and radiologist in light of all the circumstances presented in an individual examination.